Skip to main content
Much has been written about tapering medications in rheumatic diseases, often due to high costs of medications, a desire to avoid side effects and patient preference to take less medications (especially if they have side effects). This is countered by something we all know: medications not taken don’t work, and those that are frequently missed may not provide optimal outcomes for the majority of patients.
RT @RichardPAConway: Raadsen et al. RA-specific CV risk specifically targets pre-existing atherosclerotic vessels. So if

Richard Conway RichardPAConway

3 years 10 months ago
Raadsen et al. RA-specific CV risk specifically targets pre-existing atherosclerotic vessels. So if no baseline CVD, traditional risk factors are main driver rather than RA. Risk without prevalent CVD (HR 1.16 95%CI 0.88 –1.53) @RheumNow #ACR22 Abstr#1408 https://t.co/1Y6WeEFmim https://t.co/qG3RMNnbqt
RT @RichardPAConway: Michailidou et al. PMR has increased neutrophil activation and NET formation. Elevated calprotectin

Richard Conway RichardPAConway

3 years 10 months ago
Michailidou et al. PMR has increased neutrophil activation and NET formation. Elevated calprotectin. Immune complexes assoc neutrophil activation. Neutrophil activation inhibited by FcγRIIA blockade @RheumNow #ACR22 Abstr#1545 https://t.co/EAqZ3byMoP https://t.co/T2PmIExSKj
RT @EBRheum: Another poster from my research group!

Investigated recommendations in ACR/EULAR guidelines

<1/6th in

Mike Putman EBRheum

3 years 10 months ago
Another poster from my research group! Investigated recommendations in ACR/EULAR guidelines <1/6th informed by head 2 head RCT We need more comparative effectivness research! #ACR22 @RheumNow #1284 https://t.co/HQoeKj0cxy
RT @RichardPAConway: Moura et al. 22 case series of VEXAS. Lung involvement common, Symptoms in 95%. HRCT abnormal 73%.

Richard Conway RichardPAConway

3 years 10 months ago
Moura et al. 22 case series of VEXAS. Lung involvement common, Symptoms in 95%. HRCT abnormal 73%. PFTs abnormal 20%. Changes non specific inflammatory parenchymal, steroid responsive. @RheumNow #ACR22 Abstr#1569 https://t.co/E6vUnvxSdQ https://t.co/l4aEmpy8OX
RT @RichardPAConway: Fukui et al. Association different alcoholic drinks and urate in Japan. Patients always ask about t

Richard Conway RichardPAConway

3 years 10 months ago
Fukui et al. Association different alcoholic drinks and urate in Japan. Patients always ask about this. We should drink more sake it seems! @RheumNow #ACR22 Abstr#1206 https://t.co/En5pSMUNp7 https://t.co/c67r9fsHJT
RT @EBRheum: Exciting trial for PMR, SAPHYR RCT of sarilumab (IL6) in relapsing/refractory PMR

I interviewed Robert Spe

Mike Putman EBRheum

3 years 10 months ago
Exciting trial for PMR, SAPHYR RCT of sarilumab (IL6) in relapsing/refractory PMR I interviewed Robert Speira aobut the trial for @RheumNow, arriving to your podcast inbox! Overall very exciting, need options for this group and nice to see PMR getting attention #ACR22 #ACRBest https://t.co/nPurVhpNws
RT @RichardPAConway: Johnson et al. Increased risk of heart failure and heart failure mortality in RA. No improvement ov

Richard Conway RichardPAConway

3 years 10 months ago
Johnson et al. Increased risk of heart failure and heart failure mortality in RA. No improvement over time. @RheumNow #ACR22 Abstr#1204 https://t.co/MGEgmORGuL https://t.co/9zDYjZiCh1
RT @RichardPAConway: Ferrada @maferradastrong et al. HSCT in VEXAS. 20 evaluated. Indications refractory disease or haem

Richard Conway RichardPAConway

3 years 10 months ago
Ferrada @maferradastrong et al. HSCT in VEXAS. 20 evaluated. Indications refractory disease or haematologic abnormalities. Completed in 2, ongoing in 2. @RheumNow #ACR22 Abstr#1568 https://t.co/01SeHQcIsh https://t.co/XCgz4cTQCJ
RT @Janetbirdope: What to do? Should you cycle TNFi in PsA and SpA or move on? 86 Pts from CorEvitas w PsA or Ankylosing

Janet Pope Janetbirdope

3 years 10 months ago
What to do? Should you cycle TNFi in PsA and SpA or move on? 86 Pts from CorEvitas w PsA or Ankylosing spondylitis. TNF switching was not a home run - at 6 mo on 2nd TNF only 15% were in low disease activity. 21% persistence at 2 yrs. Use another Rx! Abst#1499 #ACR22 @rheumnow
RT @DrCassySims: Inflammation causing HTN in AS?

Abstract #0384 #ACR22 @RheumNow

🫀413 patients followed for median

Catherine Sims, MD DrCassySims

3 years 10 months ago
Inflammation causing HTN in AS? Abstract #0384 #ACR22 @RheumNow 🫀413 patients followed for median 12 years 🫀14% developed HTN 🫀Baseline disease duration was an independent RF for HTN 🫀ESR > 20 sig. associated with HTN
RT @RichardPAConway: Martín-Varillas et al. ADA vs certolizumab in Cystoid Macular Edema in Behcets. "Equally" effectiv

Richard Conway RichardPAConway

3 years 10 months ago
Martín-Varillas et al. ADA vs certolizumab in Cystoid Macular Edema in Behcets. "Equally" effective here but 80% of the certolizumab patients were previously refractory to ADA. @RheumNow #ACR22 Abstr#1567 https://t.co/ZKr38i2iA5 https://t.co/Jbtqlv9YAF
RT @ericdeinmd: Ab1011 #ACR22
@SMerjanah: Fracture rates among vets with AS
Increasing fx incidence for AS and comparato

Eric Dein ericdeinmd

3 years 10 months ago
Ab1011 #ACR22 @SMerjanah: Fracture rates among vets with AS Increasing fx incidence for AS and comparator groups over time There was increase in fractures during TNFi era 2004-2021 compared to pre-TNFi, does not show fx sparing effect @RheumNow https://t.co/fTSYbFcxqo
×